Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment

被引:4
|
作者
Fan, Lianlian [1 ]
Tong, Weifang [2 ]
Wei, Anhui [3 ]
Mu, Xupeng [4 ]
机构
[1] Jilin Univ, Dept Pharm, China Japan Union Hosp, Changchun 130033, Peoples R China
[2] Second Hosp Jilin Univ, Dept Otolaryngol Head & Neck Surg, Changchun 130021, Peoples R China
[3] Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Peoples R China
[4] Jilin Univ, Sci Res Ctr, China Japan Union Hosp, Changchun 130033, Peoples R China
关键词
Proteolysis targeting chimeras; PROTAC; E3 ubiquitin ligase; Cereblon; Delivery systems; Von Hippel-Lindau; E3 UBIQUITIN LIGASE; INDUCED PROTEIN-DEGRADATION; SMALL MOLECULES; DRUG; NANOPARTICLES; BROMODOMAIN; INHIBITION; DISCOVERY; KNOCKDOWN; COMPLEX;
D O I
10.1016/j.ijbiomac.2024.133680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolysis targeting chimeras (PROTACs) can use the intrinsic protein degradation system in cells to degrade pathogenic target proteins, and are currently a revolutionary frontier of development strategy for tumor treatment with small molecules. However, the poor water solubility, low cellular permeability, and off-target side effects of most PROTACs have prevented them from passing the preclinical research stage of drug development. This requires the use of appropriate delivery systems to overcome these challenging hurdles and ensure precise delivery of PROTACs towards the tumor site. Therefore, the combination of PROTACs and multifunctional delivery systems will open up new research directions for targeted degradation of tumor proteins. In this review, we systematically reviewed the design principles and the most recent advances of various PROTACs delivery systems. Moreover, the constructive strategies for developing multifunctional PROTACs delivery systems were proposed comprehensively. This review aims to deepen the understanding of PROTACs drugs and promote the further development of PROTACs delivery system.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Proteolysis targeting chimeras (PROTACs) in cancer therapy
    Ocana, Alberto
    Pandiella, Atanasio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [22] Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
    Burslem, George M.
    Crews, Craig M.
    CELL, 2020, 181 (01) : 102 - 114
  • [23] Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation
    Mou, Yi
    Wen, Shuai
    Gao, Xinxing
    Jiang, Zheng-Yu
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (03) : 139 - 141
  • [24] Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
    Jin, Yerim
    Lee, Yeongju
    CHEMMEDCHEM, 2024, 19 (23)
  • [25] In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
    Tomoshige, Shusuke
    Ishikawa, Minoru
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 41
  • [26] Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
    Wu, Yangping
    Zhang, Jingliao
    Zhu, Xiaofan
    Zhang, Yingchi
    CANCER LETTERS, 2022, 544
  • [27] Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
    Bakulina, Olga
    Sapegin, Alexander
    Bunev, Alexander S.
    Krasavin, Mikhail
    MENDELEEV COMMUNICATIONS, 2022, 32 (04) : 419 - 432
  • [28] PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
    Khan, Sajid
    He, Yonghan
    Zhang, Xuan
    Yuan, Yaxia
    Pu, Shaoyan
    Kong, Qingpeng
    Zheng, Guangrong
    Zhou, Daohong
    ONCOGENE, 2020, 39 (26) : 4909 - 4924
  • [29] PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
    Sajid Khan
    Yonghan He
    Xuan Zhang
    Yaxia Yuan
    Shaoyan Pu
    Qingpeng Kong
    Guangrong Zheng
    Daohong Zhou
    Oncogene, 2020, 39 : 4909 - 4924
  • [30] Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
    Liu, Li
    Shi, Lihong
    Wang, Zhaodi
    Zeng, Jun
    Wang, Yue
    Xiao, Hongtao
    Zhu, Yongxia
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13